CTOR (Citius Oncology, Inc.) Forward P/E Multiple

Official company branding of Citius Oncology (CTOR)

The price action of Citius Oncology, Inc. (CTOR) securities on the GURU.Markets platform helps assess the effectiveness of the company's strategy, where the indicator stands at 0.00. The business relies on bringing unique, patent-protected hematologic oncology drugs to market. Additionally, the firm is developing a network for implementing targeted therapies, although it faces stringent price controls and safety regulations from the FDA.

Citius Oncology - CTOR Forward P/E Multiple (period 08/14/2024 - 11/15/2026)

Summary analytical data breakdowns for Citius Oncology, Inc. (CTOR)

- current price and projected stock value:
Fundamental company analysis:Citius Oncology Inc
Brand item of Citius Oncology Inc

As a portfolio manager, I view this asset through the lens of market expectations. The metric compares the current market value of the stock with projected net income, reacting instantaneously to adjustments in management guidance. By analyzing the forward P/E chart, an investor determines the degree of business overvaluation relative to future earnings. For Citius Oncology, Inc. (CTOR), an increase in this indicator reflects market confidence in the expanding share of targeted therapies. Stable demand across specialized clinics makes this indicator critical for assessing capitalization potential.

Main competitors

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple